HER-2过表达胃癌和肠癌的治疗进展.pptxVIP

;;Introduction;HER2+ Metastatic Gastric Cancer;Case Study 1History Diagnosis;Case Study 1History Diagnosis;Biomarker-Guided Therapies in GCJapanese Perspective;Biomarker-Guided Therapies in GCJapanese Perspective;Biomarker-Guided Therapies in GCJapanese Perspective;Biomarker-Guided Therapies in GCJapanese Perspective;Biomarker-Guided Therapies in GCJapanese Perspective;Biomarker-Guided Therapies in GCUS Perspective: PD-1 Inhibitors in Clinical Trials;Biomarker-Guided Therapies in GCUS Perspective: NCCN Guidelines;Biomarker-Guided Therapies in GCUS Perspective: NGS Testing;Biomarker Testing Recommendations in GCFrench Perspective;First-Line Trastuzumab in HER2+ GC or GEJ CancerToGA Study Key Results;HER2 Positivity Rates in GC;HER2 Positivity Rates in GC;Clinical Relevance of HER2 Testing in GC;Clinical Relevance of HER2 Testing in GC;Use of IHC for HER2 Screening in GC;Use of IHC for HER2 Scoring in GC;Use of IHC for HER2 Scoring in GC;Use of IHC for HER2 Scoring in GC;HER2 Low Scores (1+ and 2+ Non-Amplified);HER2 Positive Scores (3+ Amplified);HER2 Positive Scores (3+ Amplified);Case Study 1Tumor Profile;Case Study 1Treatment Approach;First-Line Pembrolizumab + SoC in HER2+ GC KEYNOTE-811 Interim Analysis Key Results ;First-Line Treatment Approach for HER2+ GCPerspectives by Region;First-Line Treatment Approach for HER2+ GCPerspectives by Region;Case Study 1Progression;Heterogeneous HER2 Expression in GC;Later-Line Treatment Approach for HER2+ GCPerspectives by Region;Later-Line Treatment Approach for HER2+ GCPerspectives by Region;Later-Line Treatment Approach for HER2+ GCPerspectives by Region;Case Study 1Clinical Trial Enrollment;Trastuzumab Deruxtecan in HER2+ GC or GEJ CancerDESTINY-Gastric02 Efficacy;Case Study 1Further Progression;HER2+ Metastatic Colorectal Cancer;Case Study 2History;Biomarker Testing Recommendations in CRCUS Perspective;Case Study 2Further Investigations;First-Line Treatment Approach for HER2+ CRCPerspectives